- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | TRANSTHERA-B (02617): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| TRANSTHERA SCIENCES Aktie jetzt für 0€ handeln | |||||
| Do | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON COMMERCIALISATION OF CORE PRODUCT YOCHANRA | 3 | HKEx | ||
| 21.09. | TRANSTHERA-B (02617): INTERIM REPORT 2026 | 1 | HKEx | ||
| 18.09. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH NOVEL HORMONAL THERAPY ... | - | HKEx | ||
| 18.09. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF YOCHANRA (TINENGOTINIB) IN THE CSCO GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF BILIARY TRACT ... | 1 | HKEx | ||
| 26.08. | TRANSTHERA-B (02617): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 | - | HKEx | ||
| 14.08. | TRANSTHERA-B (02617): DATE OF BOARD MEETING | - | HKEx | ||
| 07.08. | TransThera's resistant biliary cancer drug cleared in China | - | pharmaphorum | ||
| 06.08. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT MARKETING APPROVAL FOR YOCHANRA (TINENGOTINIB TABLETS) GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | - | HKEx | ||
| 24.07. | TRANSTHERA-B (02617): GRANT OF SHARE AWARDS AND SHARE OPTIONS UNDER THE H SHARE AWARD SCHEME | 1 | HKEx | ||
| 17.07. | TRANSTHERA-B (02617): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 10.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT APPROVAL FOR CONDUCTING CHINA PHASE II CLINICAL TRIAL OF TT-00973 TABLETS IN COMBINATION WITH FIRMONERTINIB ... | 2 | HKEx | ||
| 06.07. | TransThera Completes Late-Stage Trial Enrollment For Bile Duct Cancer Drug | 3 | Benzinga.com | ||
| 01.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT ENROLLMENT COMPLETED IN THE GLOBAL MULTICENTER REGISTRATIONAL PHASE III CLINICAL TRIAL OF TINENGOTINIB MONOTHERAPY ... | 2 | HKEx | ||
| 01.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT APPROVAL GRANTED FOR PHASE II CLINICAL TRIAL IN CHINA OF TT-01488 TABLETS IN COMBINATION WITH ANTI-CD20 MONOCLONAL ... | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE STRATEGY COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): ARTICLES OF ASSOCIATION | 2 | HKEx |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,935 | +4,94 % | EQT lässt für Qiagen 9,6 Milliarden Euro springen | Der schwedische Private-Equity-Investor EQT übernimmt den europäische Molekulardiagnostik-Spezialisten Qiagen. Mit 9,6 Mrd. Euro ist die Transaktion eine der größten Übernahmen im europäischen Gesundheitssektor... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,950 | +0,07 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| VERA THERAPEUTICS | 29,050 | 0,00 % | Vera Therapeutics plans FDA filing for IgAN drug in Q4 2026 | ||
| NURIX THERAPEUTICS | 25,510 | 0,00 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| KINIKSA PHARMACEUTICALS | 80,79 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,040 | +0,03 % | Harmony Biosciences drops amid court hearing on Wakix patent | ||
| ADMA BIOLOGICS | 10,950 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 32,200 | 0,00 % | Arcutis BioTherapeutics advances 11% to new 52-week high | ||
| SUMMIT THERAPEUTICS | 15,555 | +0,03 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 12,340 | 0,00 % | What's Going On with MoonLake Immunotherapeutics Stock on Thursday? | ||
| RAPPORT THERAPEUTICS | 26,530 | 0,00 % | Jones Trading raises Rapport Therapeutics price target on pipeline potential | ||
| IMMUNOME | 18,260 | 0,00 % | William Blair initiates Immunome stock coverage with outperform rating | ||
| ARCUS BIOSCIENCES | 19,320 | -0,16 % | Arcus Biosciences prices $250M public offering at $17.50 per share | ||
| RECURSION PHARMACEUTICALS | 3,580 | 0,00 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast | ||
| ABSCI | 9,370 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen |
Das Unternehmen TRANSTHERA SCIENCES NANJING INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,960 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSTHERA SCIENCES NANJING INC finden Sie auf Wallstreet Online.